Zika vaccine candidate receives FDA Fast Track designation: Takeda announces

Takeda Pharmaceutical Company Limited announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TAK-426, Takeda's purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate. The FDA's Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions and ["]

The post Zika vaccine candidate receives FDA Fast Track designation: Takeda announces appeared first on Outbreak News Today.